With more people using PrEP every month, AVAC and its HIV Prevention Market Manager project has created the Global PrEP Tracker to help keep track of the fast-changing status of PrEP around the world.
PrEP Brasil was a demonstration study to assess feasibility of daily oral tenofovir diphosphate disoproxil fumarate plus emtricitabine provided at no cost to men who have sex with men (MSM) and transgender women at high risk for HIV within the Brazilian public health system.
This month the European parliament said it welcomed any attempts to ban the therapy, and urged all member states to “adopt similar measures that respect and uphold the right to gender identity and gender expression”.
In Gert Sibande and Ehlanzeni, two districts to the east of Johannesburg in South Africa, a study was conducted to see if HIV self-testing is feasible among men who have sex with men.
HIV self-testing is feasible and acceptable for men who have sex with men (MSM) and transgender women (TGW), engaging more people than usual testing services, according to the results of a randomised trial in Burma
